| TruScreen®
is ideally suited to those markets where there
is absent or poorly performing cytology because: |
| • |
low capital set
up costs |
| • |
no additional health
infrastructure required |
| • |
cost per service
comparable to PAP cytology and significantly
cheaper than liquid based cytology and DNA
based screening products (HPV). |
| |
TruScreen®
distribution is global through a network of
specialist / expert national medical product
distributors, together with Direct Access
Program (DAP) which is supported by PLT operations
in Sydney and London (New Malden).
Current Distributors: |
| • |
East Asia: China
- Korea - Taiwan |
| • |
South East Asia: Malaysia -
Indonesia |
| • |
South Asia: India
|
| • |
Middle East: Egypt - UAE
|
| • |
Europe: Greece - Hungary -Turkey
|
| • |
Africa: South Africa
|
Size of the market -
Screening populations
|
Region
|
Woman
aged between
18 and 65
|
| East Asia: China
- Korea - Taiwan |
491,000,000
|
South East Asia:
Malaysia - Indonesia |
78,000,000
|
| South Asia: India |
325,000,000
|
| Middle East: Egypt
- UAE |
22,000,000
|
|
Europe:Greece - Hungary - Turkey
|
50,000,000
|
| Africa: South
Africa |
14,000,000
|
| Total |
965,000,000
|
|
